Floatz logo

Hydroxychloroquine

Cutaneous Melanoma

ECOG-ACRIN Cancer Research GroupSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

141 Active assets in the Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB
Cis-Diamminedichloroplatinum Ii
MIPO Clinic
Phase 3BBB
Dacarbazine
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Hydroxychloroquine is also rated in:

pancreatic adenocarcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
malignant pancreatic neoplasmActive
B
Indicative · Phase 2
60 / 100
View asset →
hepatocellular carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →